StreetAlpha.app
Home › Stocks › MBRX

Moleculin Biotech, Inc. (MBRX)

$7.74
▼ −2.40%
LAST CLOSE · NOV 20

Moleculin Biotech develops drug candidates for hard to treat cancers and viruses, led by Annamycin. It last closed at $7.74 on Nov 20, down 2.40% on the day. The next earnings report for MBRX is expected around Thu, Mar 18, 2027. For the quarter ended Sep 2026, MBRX reported EPS of -$9.59 on revenue of $0. Over its last 8 reports the stock moved an average of 4.8% the session after earnings.

AI Auto Pilots
Is MBRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MBRX.

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$11.4M
Valuation
Market cap
$8.2M
1.1M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$7.3M
At Sep 30
Shareholder equity
$14.5M
Shares outstanding
1.1M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From MBRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 18
Estimated date · Time not announced
Reported EPS
-$9.59
Quarter ended Sep 2026
Year ago EPS
-$340.43
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$182.45Dec '24Mar 2025: -$15.80Mar '25Jun 2025: -$28.68Jun '25Sep 2025: -$340.43Sep '25Dec 2025: $1150.61Dec '25Mar 2026: -$3.54Mar '26Jun 2026: -$1.40Jun '26Sep 2026: -$9.59Sep '26Latest -$9.59
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How MBRX moved after its last 8 reports
Average move the session after a report ±4.8%
Nov 16, 2026Time not announced−9.3%
Aug 14, 2026Time not announced+7.2%
May 15, 2026Time not announced−4.1%
Mar 19, 2026Time not announced−1.0%
Aug 13, 2025Time not announced+1.9%
May 14, 2025Time not announced−7.2%
Mar 24, 2025Time not announced−2.8%
Nov 12, 2024Time not announced+5.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MBRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MBRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MBRX

Technical Analysis

MBRX · as of the Nov 20 close · updated each morning
Downtrend

The stock is 4% below its 20 day and 18% below its 50 day average. It is 345% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the swing low (Nov 2) at $7.65, and the nearest resistance the Pivot at $7.90.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 12.4%/day
Key levels
$227.0552 week high+2833.5%
$34.43200 day average+344.8%
$16.66100 day average+115.2%
$9.1650 day average+18.3%
$8.90Swing high (Nov 12)+15.0%
$8.24Pivot R1+6.5%
$8.0720 day average+4.3%
$7.90Pivot+2.1%
$7.74Last close
$7.65Swing low (Nov 2)−1.2%
$7.41Pivot S1−4.3%
$3.2352 week low−58.3%
Indicators
RSI (14)46.17Middle of its rangeNeutral
MACD-0.43Above its signal lineBullish
Stochastic36.4Middle of its rangeNeutral
ADX (14)14.1No clear trend
Williams %R-52.1Oversold below −80, overbought above −20Neutral
CCI (20)-25.8Oversold below −100, overbought above 100Neutral
Rate of change−11.0%Change over 10 sessionsBearish
ATR (14)$0.96Typical daily range, 12.4% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MBRX

What happened before

See how MBRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow MBRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How MBRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for MBRXHow many large options trades hit MBRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

MBRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲11 buying vs 5 selling
  • ▲Held by funds +40.1 pts
  • ▲Funds holding +3
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2320+15.0%
In funds' top 1000–
Held by funds59.5%19.4%+40.1 pts
New / increased7 / 46 / 8−21.4%
Reduced / sold out2 / 30 / 7−28.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MBRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MBRX Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 23, 2025Walter V KlempCEO and PresidentBuy675,675$0.37$250K
Jun 23, 2025Jonathan P. FosterCFOBuy270,270$0.37$100K
Every insider buy and sale for MBRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MBRX insider trades →

From SEC Form 4 filings by MBRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MBRX is in one of them and how their past MBRX trades turned out.

MBRX in the AI portfolios
Loading…

MBRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MBRX in an article yet. Here's the latest on the wider market.

MBRX in the news

About Moleculin Biotech

Moleculin Biotech is a pharmaceutical development company based in Houston, Texas, that develops drug candidates for cancer and certain viruses. Its lead candidate, Annamycin, is an anthracycline chemotherapy agent being studied for relapsed or refractory acute myeloid leukemia and for soft tissue sarcoma that has spread to the lungs. Much of its research is carried out with academic investigators, including at MD Anderson Cancer Center in Houston.

Headquarters
Houston, TX